TT-P34 Advances as Teitur Trophics Completes Phase I MAD Cohort in Parkinson’s Patients

Teitur Trophics reached an important milestone in the clinical development journey for TT-P34. In the Phase I trial the last participant has completed dosing in the Multiple Ascending Dose extension cohort, investigating safety and pharmacokinetics in Parkinson’s disease patients.

‍

“This marks a significant step forward in advancing TT‑P34, our dual enhancer of lysosomal and mitochondrial function, designed as first-in-class treatment to address the underlying biology of Parkinson’s disease.” said Dr. Simon Molgaard, CEO of Teitur Trophics.

‍

This achievement reflects the dedication of our clinical partners, the trust of our participants, and the strength of our scientific vision that enhancing lysosomal and mitochondrial function in parallel is a key factor to delay progression in Parkinson’s disease. A huge thank you to the participants, their families, and the exceptional team at Centre for Human Drug Research (CHDR) for their commitment and collaboration.

‍

These results confirm the safety data from healthy volunteers, presented in March during the AD/PD conference in Copenhagen, which importantly demonstrate that TT‑P34 was well tolerated on top of standard Parkinson’s medications. “We are encouraged by the excellent safety and tolerability profile observed in the patient population. This is a key step forward as we prepare for the next phase of clinical development.” said Dr. Andreas Borta, CMO of Teitur Trophics.

‍

This achievement comes at a fitting moment during Parkinson’s Awareness Month, when global attention turns to the urgent need for therapies that can truly change the course of this disease. It reflects the rapid progress of Teitur's entire team on our journey to develop a new disease‑modifying treatment grounded in strong human biology and lysosomal enhancement.

‍